Turn Therapeutics financials
$13.41+2.84%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — |
| Operating income | -$1.6M | -$1.2M | -$2.2M |
| Net income | -$5.8M | -$971.0K | $279.1K |
| Net margin | — | — | — |
| Diluted EPS | $-0.20 | $-0.03 | $0.01 |
| EBITDA | -$1.6M | -$1.2M | -$2.2M |
| Operating cash flow | -$923.4K | -$1.6M | -$1.2M |
| Free cash flow | -$923.4K | -$1.6M | -$1.2M |
| Diluted shares | 29.8M | 29.5M | 28.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $10.3M | $11.2M | $5.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $6.1M | $5.9M | $0.00 |
| Total assets | $17.0M | $18.6M | $12.2M |
| Total liabilities | $16.3M | $12.5M | $7.5M |
| Shareholders' equity | $686.9K | $6.1M | $4.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology